PACAP for Retinal Health: Model for Cellular Aging and Rescue

Area of Science:

• Neuroscience
• Ophthalmology
• Aging Research

Background:

• Retinal aging involves cellular damage and visual function decline.
• Somatostatin (SST) and PACAP are neuroprotective agents.
• A reliable transgenic model for SST-expressing amacrine cells is needed.

Purpose of the Study:

• Validate a transgenic model for SST-expressing amacrine cells.
• Investigate the chronic effect of PACAP on aging retinal SSTergic and dopaminergic cells.

Main Methods:

• Used SST-tdTomato transgenic mice aged 6, 12, and 18 months.
• Administered PACAP intravitreally every 3 months.
• Assessed SST and dopaminergic amacrine cell density in retinal whole mounts.

Main Results:

• PACAP treatment moderately elevated SST and dopaminergic cell densities in 12- and 18-month-old mice.
• Control retinas showed minor cell loss with age.
• Identified transgenic red fluorescence for SST-immunopositive amacrine cells.

Conclusions:

• A reliable transgenic model for studying SSTergic amacrine cells was developed.
• PACAP demonstrated potential to increase cell density in aged retinal tissue.
• PACAP may hold therapeutic promise for age-related retinal pathologies.